Download file (92.8 KB)
Download as zip (88.7 KB)

Collection

Citation

Description:

Therapeutic cancer vaccines aim to train the immune system and elicit antitumor immune responses, which are expected to fill the unmet medical need of immune checkpoint inhibitors. Despite tremendous efforts over the past decades, it remains challenging to prepare personalized cancer vaccines using a facile and rapid approach due to tumor diversity. CpG-ODN is a promising immunoadjuvant in cancer immunotherapy, and many clinical trials have been performed or are ongoing. However, commonly used phosphorothioate-modified CpG ODN easily induces protein aggregation and its long-term side effects are concerned. Here, we designed hollow large-pore mesoporous organosilica with sulfide bond to simultaneously load unmodified CpG-ODN with guanine-quadruplex (G4) structures and different tumor antigens to prepare personalized cancer vaccines in a simple, fast, and effective way.

Rights:

• In Copyright
  

Keyword: personalized, cancer nanovaccines, CpG-ODN, mesoporous organosilica

Date published: 2024-06-01

Publisher: American Society of Clinical Oncology (ASCO)

Journal:

• Journal of Clinical Oncology (ISSN: 0732183X) vol. 42 issue. 16_suppl

Funding:

• Japan Society for the Promotion of Science (JSPS), KAKENHI 23K04555 and 22K20517
• NIMS

Manuscript type: Author's version (Accepted manuscript)

MDR DOI: https://doi.org/10.48505/nims.4762

First published URL: https://doi.org/10.1200/jco.2024.42.16_suppl.e14670

Related item:

Other identifier(s):

Contact agent:

Updated at: 2025-05-30 08:30:07 +0900

Published on MDR: 2025-05-30 08:17:58 +0900